The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 15, 2025

Filed:

Dec. 11, 2015
Applicant:

Etagen Pharma, Inc., Sudbury, MA (US);

Inventors:

Tod M. Woolf, Sudbury, MA (US);

Alexandre V. Lebedev, Sudbury, MA (US);

Richard I. Hogrefe, San Diego, CA (US);

Assignee:

Etagen Pharma, Inc., Sudbury, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C12N 15/10 (2006.01);
U.S. Cl.
CPC ...
C12N 15/111 (2013.01); C12N 15/102 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/333 (2013.01); C12N 2310/335 (2013.01); C12N 2310/344 (2013.01); C12N 2310/351 (2013.01); C12N 2320/34 (2013.01);
Abstract

The present invention includes compositions and methods for the treatment of a medical condition or disease utilizing editing oligonucleotides. The editing oligonucleotides contain an oligonucleotide strand of about 10 to about 50 nucleotides on each side of the editing moiety which may contain a sugar or linker that positions the active editing moiety in the proper location for hybridization to the target nucleic acid. The editing oligonucleotides may also contain at least one nucleotide sequence change from the targeted sequence in the genome. The method includes modifying a genomic sequence within a cell utilizing an editing oligonucleotide without additional proteins or nucleic acids to assist in the editing process. The editing oligonucleotide may comprise backbone modifications that increase the nuclease stability of the oligonucleotide as compared to unmodified oligonucleotides or oligonucleotides having three phosphorothioates on each terminus.


Find Patent Forward Citations

Loading…